XM levert geen diensten aan inwoners van de Verenigde Staten.
M
M

McKesson


Nieuws

McKesson, Cencora & Cardinal Health vying to buy Florida Cancer Specialists & Research Institute- Bloomberg News

MEDIA-McKesson, Cencora & Cardinal Health vying to buy Florida Cancer Specialists & Research Institute- Bloomberg News -- Source link: https://tinyurl.com/27qkdtlg -- Note: Reuters has not verified this story and does not vouch for its accuracy
M

U.S. Alphabet, Domino's Pizza, McKesson

U.S. RESEARCH ROUNDUP-Alphabet, Domino's Pizza, McKesson July 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alphabet, Domino's Pizza and McKesson, on Tuesday. HIGHLIGHTS * Alphabet Inc GOOGL.O : Jefferies raises target price to $220 from $215 * Domino's Pizza Inc DPZ.N : Baird raises to outperform; raises target to $580 from $530 * McKesson Corp MCK.N : Baird raises target price to $694 from $679 * Teleflex Inc T
A
A
C
C
G
M
C
A
C
T

Rite Aid bankruptcy plan approved, cutting $2 bln in debt

UPDATE 2-Rite Aid bankruptcy plan approved, cutting $2 bln in debt Updates throughout By Dietrich Knauth NEW YORK, June 28 (Reuters) - A U.S. bankruptcy judge on Friday approved Rite Aid's restructuring plan, allowing the pharmacy chain to cut its debt by $2 billion and turn over control to a group of lenders. U.S. Bankruptcy Judge Michael Kaplan approved Rite Aid's bankruptcy plan at a court hearing in Trenton, New Jersey, saying that the restructuring had saved the company from having to shut
M

Rite Aid seeks bankruptcy court approval to cut $2 billion debt

Rite Aid seeks bankruptcy court approval to cut $2 billion debt By Dietrich Knauth NEW YORK, June 27 (Reuters) - Rite Aid will ask a U.S. bankruptcy court to approve its restructuring plan on Thursday, seeking to cut $2 billion in debt and turn over control of the company to a group of its lenders. One of the largest U.S. pharmacy chains, Rite Aid has said in court filings that the restructuring is the best way to pay its creditors and emerge from bankruptcy.
M

US law firm Motley Rice appeals $396 mln opioid fee award

US law firm Motley Rice appeals $396 mln opioid fee award By Brendan Pierson June 24 (Reuters) - U.S. law firm Motley Rice is appealing its award of $396 million for its work on litigation against the drug industry over the opioid crisis that resulted in $46 billion in nationwide settlements. The firm said it would appeal the award, which represents 18.6% of a $2.13 billion pool of fees to be divided among dozens of law firms, in a notice filed Friday in Cleveland federal court.
T
W
M

Top law firms in US opioid lawsuits to get hundreds of millions in fees

Top law firms in US opioid lawsuits to get hundreds of millions in fees By Brendan Pierson June 7 (Reuters) - A court-appointed panel on Friday recommended how to divvy up a pool of $2.13 billion in legal fees from nationwide drug industry settlements over the U.S. opioid crisis, with top firms set to receive hundreds of millions of dollars. The panel gave national firm Motley Rice the largest share, with 18.6% of the funds, or $396 million.
T
W
M

Tesla director Gebbia says he discussed selling house to Musk

EXCLUSIVE-Tesla director Gebbia says he discussed selling house to Musk By Rachael Levy June 3 (Reuters) - Joe Gebbia, the Tesla TSLA.O director who exited a board committee that made key decisions about the car maker's future, told Reuters that CEO Elon Musk had discussed purchasing a house from his start-up and that he was concerned their friendship could be seized on to attack the committee's independence.
D
M
T
W
M

U.S. Autodesk, McKesson, MicroStrategy

U.S. RESEARCH ROUNDUP-Autodesk, McKesson, MicroStrategy May 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, McKesson and Microstrategy, on Wednesday. HIGHLIGHTS * Analog Devices Inc ADI.O : Raymond James raises target price to $260 from $215 * Autodesk Inc ADSK.O : Baird cuts target price to $289 from $296 * Cencora Inc COR.N : Baird raises target price to $280 from $277 * McKesson Corp MCK.N : Baird rai
A
C
S
A
A
U
D
M
L
M

Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont

BRIEF-Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont May 15 (Reuters) - Third Point LLC: THIRD POINT LLC TAKES SHARE STAKE OF 3.0 MILLION SHARES OF CLASS A CAPITAL STOCK - SEC FILING THIRD POINT LLC TAKES SHARE STAKE OF 1.5 MILLION SHARES IN ADVANCE AUTO PARTS INC THIRD POINT LLC DISSOLVES SHARE S
B
G
U
M
A

U.S. Adtran Holdings, McKesson, Waters Corp

U.S. RESEARCH ROUNDUP- Adtran Holdings, McKesson, Waters Corp May 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adtran Holdings, McKesson and Waters Corp, on Wednesday. HIGHLIGHTS * Adtran Holdings Inc ADTN.O : Jefferies cuts target price to $8.5 from $10.5 * Beyond Inc BYON.N : Jefferies cuts target price to $18 from $29 * Freshpet Inc FRPT.O : Stephens raises target price to $145 from $130 * McKesson Corp MCK.N
A
G
M
W
A
A

McKesson misses quarterly estimates as US pharmaceuticals segment weighs

McKesson misses quarterly estimates as US pharmaceuticals segment weighs May 7 (Reuters) - McKesson Corp MCK.N reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical segment. The drug distributor's pharmaceutical segment in the U.S.
M

Mckesson Corp reports results for the quarter ended in January - Earnings Summary

Mckesson Corp reports results for the quarter ended in January - Earnings Summary Mckesson Corp MCK.N reported quarterly adjusted earnings of $6.18​​ per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of $7.19. The mean expectation of sixteen analysts for the quarter was for earnings of $6.34 per share.
M

McKesson Q4 Adjusted EPS USD 6.18 Vs. IBES Estimate USD 6.34

BRIEF-McKesson Q4 Adjusted EPS USD 6.18 Vs. IBES Estimate USD 6.34 May 07 (Reuters) - McKesson Q4 revenue USD 76,355 million vs. IBES estimate USD 79,318 million. Q4 adjusted net income USD 813 million vs. IBES estimate USD 836.3 million Q4 EPS USD 6.02 outlook FY adjusted EPS USD 31.25-32.05
M

What to Watch in the Day Ahead - Tuesday, May 7

What to Watch in the Day Ahead - Tuesday, May 7 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Analysts expect Disney's quarterly revenue to grow by 1% in the quarter ended March.
A
B
J
M
T
E
L
M
T
J

Mckesson Corp <MCK.N> expected to post earnings of $6.34 a share - Earnings Preview

Mckesson Corp expected to post earnings of $6.34 a share - Earnings Preview Mckesson Corp MCK.N , MCK is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2024 The Irving Texas-based company is expected to report a 15.1% increase in revenue to $79.318 billion from $68.91 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
M

Cardinal Health falls on losing contracts with UnitedHealth's OptumRx

BUZZ-Cardinal Health falls on losing contracts with UnitedHealth's OptumRx Updates ** Shares of drug distributor Cardinal Health CAH.N fall ~6.2% to $101.52, its lowest since Feb. 8 ** Co says its pharma distribution contracts with UnitedHealth's UNH.N OptumRx unit will not be renewed after they expire at the end of June ** Co expects to partially offset impact of losing OptumRx contracts through combination of new customer wins and growth in its specialty pharmacy business ** Analysts at Everco
M

Drug distributor Cardinal Health to lose OptumRx contracts

UPDATE 3-Drug distributor Cardinal Health to lose OptumRx contracts Updates shares, adds analyst comment in paragraph 2 and 3 By Mariam Sunny April 22 (Reuters) - Cardinal Health CAH.N said on Monday its contracts with UnitedHealth Group's UNH.N OptumRx, one of its largest customers, will not be renewed after they expire at the end of June, sending the drug distributor's shares down about 6%.
M



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.